NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating:
Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its proposed merger with F-star Therapeutics, Limited. Under the terms of the share exchange agreement, Spring Bank will acquire all of the outstanding share capital of F-star in exchange for the issuance of newly issued shares of Spring Bank common stock. Spring Bank shareholders will own approximately 38.8% of the combined company. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/spring-bank-pharmaceuticals-inc-sbph-stock-merger-fstar/.
GCI Liberty, Inc. (NASDAQ: GLIBA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Liberty Broadband Corporation. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/gci-liberty-inc-gliba-stock-merger-liberty-broadband-technologies/.
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Under the terms of the merger, Cellular Biomedicine stockholders (excluding certain parties) will receive $19.75 in cash for each outstanding share of common stock held immediately prior to the effective time of the merger. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/cellular-biomedicine-group-inc-cbmg-stock-merger/.
Proteostasis Therapeutics, Inc. (NASDAQ: PTI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Yumanity Therapeutics. Under the terms of the merger agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/proteostasis-therapeutics-inc-pti-yumanity-stock-merger/.
Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
SOURCE: Halper Sadeh LLP